Effect on the Prevalence of Various Diffuse Parenchymal Lung Diseases due to Paradigm Change in the Guidelines
Syed Zulkharnain Tousheed, BV MuraliMohan, PH Manjunath, MRK Ravichandra, R Ranganatha, VM Annapandian, H Kumar, KR Hibare, C Sagar, T Gupta, V Raj, TS Dutt, BJ Khan
Citation Information :
Tousheed SZ, MuraliMohan B, Manjunath P, Ravichandra M, Ranganatha R, Annapandian V, Kumar H, Hibare K, Sagar C, Gupta T, Raj V, Dutt T, Khan B. Effect on the Prevalence of Various Diffuse Parenchymal Lung Diseases due to Paradigm Change in the Guidelines. Indian J Chest Dis Allied Sci 2022; 64 (4):243-246.
Background: Diffuse parenchymal lung diseases (DPLDs) have gone through various changes in nomenclature and classification since they were first described in 1868. Increasing knowledge about their etiopathogenesis has since led to several reclassifications and changes in the nomenclature. This has had a major impact on the prevalence of each interstitial lung disease (ILD) reported by the different registries worldwide. In this study, we attempted to describe the distribution of the different DPLDs in our population and reported changes in prevalence due to changing diagnostic criteria for the disease.
Materials and methods: We analyzed retrospective data of 434 patients. For the initial 75 patients, ATS/ERS guidelines published in 2002 were followed in the diagnosis of the ILD (group I). In the later part of the study (359 patients), the diagnosis was based on the computed tomography (CT) patterns defined by ATS/ERS/JPS/ALAT statement on diagnosis of idiopathic pulmonary fibrosis (IPF) and updated 2013 ATS/ERS guidelines (group II).
Results: Of the 75 patients in group I, IPF was the most common diagnosis (52%) made at that time, followed by sarcoidosis and connective tissue-related ILD (CTD-ILD) with 12% each. Group II had 359 patients, with IPF again being the most commonly diagnosed ILD with 21.3%. This was followed by CTD-ILD (18.6%), sarcoid (14.7%), and idiopathic nonspecific interstitial pneumonitis (iNSIP; 13.3%). The changing guidelines have an impact on reporting of different DPLD by our multidisciplinary teamover a period of time. Though IPF was the most commonest DPLD reported among both the groups, the diagnosis of IPF had fallen by more than half in the second group. It was paralleled by an increase in the diagnosis of iNSIP and chronic hypersensitivity pneumonitis. These reported changes in the prevalence of DPLDs may reflect the better-defined criteria in the latest guidelines and a better understanding of the fibrotic ILDs other than IPF by the multidisciplinary team.
Conclusions: The frequency of diagnosis of the different DPLDs has changed, following the publication of several guidelines in the last decade. It has recognized newer entities with greater clarity, such as idiopathic NSIP and interstitial pneumonia with autoimmune features.
Sandoz E. Uber zwei Falle von fotaler Bronchektasie. Beitr Pathol Anat 1907;41:496–517.
Liebow AA, Carrington CB. The interstitial pneumonias. In: Simon M, Potchen E., Lemay E, editors. Frontiers in Pulmonary Radiology. New York: Grune and Stratton; 1969. pp. 102–141.
American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165(2): 277–304. DOI: 10.1164/ajrccm.165.2.ats01.
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788–824. DOI: 10.1164/rccm.2009-040GL.
Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188(6):733–748. DOI: 10.1164/rccm.201308-1483ST.
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018;198(5):e44–e68. DOI: 10.1164/rccm.201807-1255ST.
Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46(4):976–987. DOI: 10.1183/13993003.00150-2015.
Tinelli C, De Silvestri A, Richeldi L, et al. The Italian register for diffuse infiltrative lung disorders (RIPID): A four-year report. Sarcoidosis Vasc Diffuse Lung Dis 2005;22(Suppl 1):S4–S8. PMID: 16457011.
Agostini C, Albera C, Bariffi F, et al. First report of the Italian register for diffuse infiltrative lung disorders (RIPID). Monaldi Arch Chest Dis 2001;56(4):364–368. PMID: 11770220.
Schweisfurth H. Report by the Scientific Working Group for Therapy of Lung Diseases: German Fibrosis Register with initial results. Pneumologie 1996;50(12):899–901. PMID: 9091884.
Schweisfurth H, Kieslich C, Satake N, et al. How are interstitial lung diseases diagnosed in Germany? Results of the scientific registry for the exploration of interstitial lung diseases (“Fibrosis registry”) of the WATL. Pneumologie 2003;57(7):373–382. DOI: 10.1055/s-2003-40557
Fruchter O, Fridel L, El Raouf BA, et al. Histological diagnosis of interstitial lung diseases by cryo-transbronchial biopsy. Respirology 2014;19(5):683–688. DOI: 10.1111/resp.12296.
Poletti V, Hetzel J. Transbronchial cryobiopsy in diffuse parenchymal lung disease: Need for procedural standardization. Respiration 2015;90:275–278. DOI: 10.1159/000439313.
Thomeer M, Demedts M, Behr J, et al. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J 2008;31(3):585–591. DOI: 10.1183/09031936.00063706.
Chaudhuri N, Spencer L, Greaves M, et al. A review of the multidisciplinary diagnosis of interstitial lung diseases: A retrospective analysis in a Single UK Specialist Centre. J Clin Med 2016;5(8):66. DOI: 10.3390/jcm5080066.
Walsh SLF, Wells AU, Desai SR, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: A case-cohort study. Lancet Respir Med 2016;4(7):557–565. DOI: 10.1016/S2213-2600(16)30033-9.
Furini F, Carnevale A, Casoni GL, et al. The role of the multidisciplinary evaluation of interstitial lung diseases: Systematic literature review of the current evidence and future perspectives. Front Med (Lausanne) 2019;6:246. DOI: 10.3389/fmed.2019.00246.
Dhooria S, Agarwal R, Sehgal IS, et al. Spectrum of interstitial lung diseases at a tertiary center in a developing country: A study of 803 subjects. PLoS One 2018;13(2):e0191938. DOI: 10.1371/journal.pone.0191938.
Singh S, Collins BF, Sharma BB, et al. Interstitial lung disease in India. Results of a prospective registry. Am J Respir Crit Care Med 2017;195(6):801–813. DOI: 10.1164/rccm.201607-1484OC.
Kumar R, Gupta N, Goel N. Spectrum of interstitial lung disease at a tertiary care centre in India. Pneumonol Alergol Pol 2014;82(3): 218–226. DOI: 10.5603/PiAP.2014.0029.
Kundu S, Mitra S, Ganguly J, et al. Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience. Lung India 2014;31(4):354–360. DOI: 10.4103/0970-2113.142115.
Sen T, Udwadia ZF. Retrospective study of interstitial lung disease in a tertiary care centre in India. Indian J Chest Dis Allied Sci 2010;52(4):207–211. PMID: 21302597.
Jindal SK, Gupta D. Incidence and recognition of interstitial pulmonary fibrosis in developing countries. Curr Opin Pulm Med 1997;3(5):378–383. DOI: 10.1097/00063198-199709000-00011.
